Related Experiment Videos
Biologic response modifiers in chronic hepatitis C
1Hepatology Unit, Fundación Jiménez Díaz, Madrid, Spain.
Insights
Biologic response modifiers like colony-stimulating factors and interleukins show promise in treating chronic viral hepatitis. Their use, alone or with interferon-alpha, is reviewed for chronic hepatitis C therapy.
Area of Science:
- Immunology
- Hepatology
- Pharmacology
Background:
- Biologic response modifiers encompass colony-stimulating factors and interleukins.
- These agents are valuable in treating diverse diseases and preventing hematologic disorders.
Purpose of the Study:
- To review the biologic effects of these modifiers.
- To examine the rationale for their use in chronic viral hepatitis.
- To assess their efficacy alone or combined with interferon-alpha for chronic hepatitis C.
Main Methods:
- Literature review of biologic response modifiers.
- Analysis of their application in viral hepatitis treatment.
- Evaluation of combination therapy with interferon-alpha.
Main Results:
- Colony-stimulating factors and interleukins demonstrate therapeutic benefits.
- These modifiers can prevent hematologic disorders.
- Their role in chronic hepatitis C treatment is under investigation.
Conclusions:
- Biologic response modifiers offer potential therapeutic strategies for chronic viral hepatitis.
- Further research is warranted to optimize their use in chronic hepatitis C.
- Combination therapy with interferon-alpha may enhance treatment outcomes.
Abstract:
Biologic response modifiers include various colony-stimulating factors and interleukins such as granulocyte-macrophage colony-stimulating factor, granulocyte colony-stimulating factor, and interleukin-2. Their use as therapy has proven to be beneficial in the treatment of various diseases, and in preventing hematologic disorders. Their biologic effects and the rationale for their use in chronic viral hepatitis, alone or in combination with interferon-alpha, are reviewed with respect to the treatment of chronic hepatitis C.